Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 14;15:47.
doi: 10.1186/s13020-020-00328-8. eCollection 2020.

Clinical Characteristics of 9 Cancer Patients With SARS-CoV-2 Infection

Affiliations
Free PMC article

Clinical Characteristics of 9 Cancer Patients With SARS-CoV-2 Infection

Yong Zeng et al. Chin Med. .
Free PMC article

Abstract

In December 2019, a cluster of pneumonia cases was caused by the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) in Wuhan, China. Cancer patients are a special group, the immunity of them will be suppressed because of various anti-tumor treatments, and the risk of infection will be greatly increased, so we will report clinical features of 9 cancer patients with SARS-CoV-2 infection. 5 (56%) patients were ordinary type, 3 (33%) were severe type, and 1 (11%) was critical type. A total of 8 patients received combined therapy of traditional Chinese medicines and western medicines. From the clinical outcomes of these 8 patients, western combined therapy of traditional Chinese medicine was indeed an effective treatment method. D-dimmer rise, infection index rise, and chest CT(computed tomography) progression may be clinical warning indicators for severe patients, in our study, more 50% of patients had elevated levels of these indicators, but only 44% (including the dead) of patients had received treatment in the intensive care unit. 5 (56%) ordinary type patients had been discharged, while the 1 (11%) critical type patient died 3 days after admission. Cancer comorbidity seems to have no direct relationship with severe events, and the combination of traditional Chinese medicine and western medicine may be effective in the prevention and treatment of novel coronavirus-infected pneumonia (NICP).

Keywords: Cancer; Clinical characteristics; Outcomes; SARS-CoV-2.

Conflict of interest statement

Competing interestsNone.

Figures

Fig. 1
Fig. 1
The median time from onset of symptoms: a to first hospital admission was 4 (1–15) days; b to 2019-nCoV positive was 5 (2–20)day; c to first chest CT images was 3 (1–10) days; d. to intensive care unit admission was 15 (2–23)days; e the median time from nCoV positive to negative was 19.5 (2–26)days

Similar articles

See all similar articles

References

    1. Novel Coronavirus (2019-nCoV). Geneva: World Health Organization, 2019. https://www.who.int/emergencies/diseases/novel-coronavirus-2019. [Accessed Jan 26, 2020].
    1. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan China: the mystery and the miracle. J Med Virol. 2020 doi: 10.1002/jmv.25678. - DOI - PMC - PubMed
    1. Kamboj M, Sepkowitz KA. Nosocomial infections in patients with cancer. Lancet Oncol. 2009;10:589–597. doi: 10.1016/S1470-2045(09)70069-5. - DOI - PubMed
    1. Li JY, Duan XF, Wang LP, et al. Selective depletion of regulatory T cell subsets by docetaxel treatment in patients with nonsmall cell lung cancer. J Immunol Res. 2014;2014:286170. - PMC - PubMed
    1. Longbottom ER, Torrance HD, Owen HC, et al. Features of postoperative immune suppression are reversible with interferon gamma and independent of interleukin-6 pathways. Ann Surg. 2016;264:370–377. doi: 10.1097/SLA.0000000000001484. - DOI - PubMed

LinkOut - more resources

Feedback